Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer

Phase 2

• Conditions: Colonic Neoplasms

• Registration Number: NCT01929499
• Lead Sponsor: Yanjuan Zhu

Brief Summary

It has been reported that the immune status of patients with cancer were suppressed, especially those after surgery and adjuvant chemotherapy. Thus, immunotherapy may decrease the recurrence rate after surgery. CIK cells transfusion has been reported as an effect therapy in advanced cancers. In another retrospective study, investigators found that adjuvant CIK therapy would prolong the disease-free survival (DFS) for colorectal cancer patients.

The purpose of this study is to determine wether adjuvant immunotherapy with CIK cells in patients with colon cancer after operation will prolong DFS, and overall survival (OS).

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-08
• Study First Submitted: 2013-08-20
• Study First Submitted QC: 2013-08-21
• Last Update Submitted: 2013-08-27
• Study First Posted: 2013-08-28
• Last Update Posted: 2013-08-29
• Study Start: 2013-09
• Primary Completion: 2016-08
• Study Completion: 2019-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

• Colon cancer in stage III or stage II with high risk after R0 resection
• Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
• Life expectancy of at least 3 months;
• Normal bone marrow, liver, renal, heart and lung function;
• Age between 18-80;
• Patients who provided written informed consent for this study

Exclusion Criteria

• With uncontrolled other malignant tumors;
• With uncontrolled infection or tubercle bacillus (TB) or underlying diseases that were severe or life threatening;
• Patients who need to treat with radiotherapy;
• Patients who accepted other immunotherapy
• With sever mental disease or disease with central nervous system (CNS);
• With the history of organ transplantation, including bone marrow transplantation or stem cell transplantation;
• Patients with auto immune diseases;
• pregnant or lactating.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
DFS (Disease free survival)	Time elapsedelapsed from the date of surgery to either the date of recurrence or the date of last follow-up information,whichever come first, assessed up to 5 years.	Patients who were recurrence free at the end of study or lost to follow-up were censored

Secondary Outcome Measures

Name	Time	Method
OS (overall survival)	Time elapsed from the date of surgery to either the date of death or the date of last follow-up information, whichever came first, assessed up to 5 years.	Patients who were survival at the end of study or lost to follow-up were censored
Side effect	Up to 2 years	Any undesirable secondary effect which occurs in addition to the desired therapeutic effect of CIK or chemotherapy, during the period from the first cycle of chemotherapy or CIK infusion to the end of study. The side effects were described according to the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events)
T lymphocyte subset	Up to 6 months	During the period of CIK infusion
QoL (quality of life)	Up to 1 year	During the period of chemotherapy and CIK infusion

Trial Locations

Locations (1)

Guangdong Provincial Hospital of Chinese Medicine; 🇨🇳 Guangzhou, Guangdong, China